Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA ≥10\^4 IU/mL at screening~* Confirmed chronic HCV genotype 1 or 3 infection~* HCV treatment naive~* Approximately 30% of individuals may have compensated cirrhosis at screening~Exclusion Criteria:~* Any other chronic liver disease~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Current or prior history of clinical hepatic de-compensation~* Contraindication to RBV therapy, e.g., history of clinically significant hemoglobinopathy (sickle cell disease, thalassemia).~* Chronic use of systemically administered immunosuppressive agents~* History of solid organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV 16 weeks (Type: EXPERIMENTAL): Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
- Sofosbuvir+RBV 24 weeks (Type: EXPERIMENTAL): Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).